JAK-STAT inhibitors in the treatment of COVID-19 patients offer a potential advantage in that they achieve their effects at already approved dosages, and some have minimal protein binding allowing for combination therapy with antiretrovirals [56]. This evidence concerns the gene SOAT1 and COVID-19.